MA27805A1 - Cristaux de derive de benzimidazole et leur procede de preparation - Google Patents

Cristaux de derive de benzimidazole et leur procede de preparation

Info

Publication number
MA27805A1
MA27805A1 MA28603A MA28603A MA27805A1 MA 27805 A1 MA27805 A1 MA 27805A1 MA 28603 A MA28603 A MA 28603A MA 28603 A MA28603 A MA 28603A MA 27805 A1 MA27805 A1 MA 27805A1
Authority
MA
Morocco
Prior art keywords
preparing
same
benzimidazole derivative
derivative crystals
crystals
Prior art date
Application number
MA28603A
Other languages
English (en)
Inventor
Mitsuru Teramoto
Naoki Tsuchiya
Hiroshi Saitoh
Original Assignee
Teijin Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33447189&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA27805(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teijin Pharma Ltd filed Critical Teijin Pharma Ltd
Publication of MA27805A1 publication Critical patent/MA27805A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

ABSTRAIT Les diverses formes en cristal de l'acide butanoïque 4-(l-((4, methylbenzothiophen-3-yl) méthyle) benzimidazol-2 ylthio) à partir du solvant, et du procédé pour la production de celui-ci sont fournies.
MA28603A 2003-05-14 2005-11-14 Cristaux de derive de benzimidazole et leur procede de preparation MA27805A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2003135567 2003-05-14

Publications (1)

Publication Number Publication Date
MA27805A1 true MA27805A1 (fr) 2006-03-01

Family

ID=33447189

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28603A MA27805A1 (fr) 2003-05-14 2005-11-14 Cristaux de derive de benzimidazole et leur procede de preparation

Country Status (25)

Country Link
US (1) US7649008B2 (fr)
EP (1) EP1626048A4 (fr)
JP (1) JPWO2004101551A1 (fr)
KR (1) KR20060011997A (fr)
CN (1) CN1788007A (fr)
AR (1) AR044340A1 (fr)
AU (1) AU2004238708A1 (fr)
BR (1) BRPI0410266A (fr)
CA (1) CA2523978A1 (fr)
CL (1) CL2004001034A1 (fr)
CO (1) CO5660259A2 (fr)
EC (1) ECSP056162A (fr)
IS (1) IS8177A (fr)
MA (1) MA27805A1 (fr)
MX (1) MXPA05011851A (fr)
NO (1) NO20055181L (fr)
NZ (1) NZ542978A (fr)
PE (1) PE20050203A1 (fr)
RU (1) RU2332417C2 (fr)
SA (1) SA04250117B1 (fr)
TN (1) TNSN05288A1 (fr)
TW (1) TW200505911A (fr)
UA (1) UA81493C2 (fr)
WO (1) WO2004101551A1 (fr)
ZA (1) ZA200508640B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2004001034A1 (es) 2003-05-14 2005-03-28 Teijin Pharma Ltd Formas cristalinas de acido 4-(1-((,etilbenzotiofen-3-il)me til)benzimidazol-2-iltio)butanoico; procedimiento de preparacion de las formas cristalinas; composicion farmaceutica; y su uso para el tratamiento de enfermedades inflamatorias, alergicas, r
KR20060120601A (ko) * 2003-08-22 2006-11-27 데이진 화-마 가부시키가이샤 키마제 저해제를 유효 성분으로서 함유하는 약제
US20080015240A1 (en) * 2004-11-12 2008-01-17 Mitsuru Teramoto Acid Salt of Benzimidazole Derivative and Crystal Thereof
JP2016150917A (ja) * 2015-02-17 2016-08-22 株式会社トクヤマ バルサルタンの結晶の製造方法
WO2022257845A1 (fr) * 2021-06-11 2022-12-15 苏州科睿思制药有限公司 Forme cristalline du tolebrutinib, son procédé de préparation et son utilisation

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3683760D1 (de) 1986-03-21 1992-03-12 Heumann Pharma Gmbh & Co Kristalline, wasserfreie sigma -form von 2-(4-(2-furoyl-(2-piperazin)-1-yl)-4-amino-6,7-dimethoxychinazolinhydrochlorid und verfahren zu ihrer herstellung.
US5015646A (en) 1987-08-28 1991-05-14 Bristol-Myers Squibb Co. Pharmaceutically useful polymorphic modification of buspirone
CN1048239C (zh) 1994-05-31 2000-01-12 帝人株式会社 萘衍生物
ES2150353B1 (es) 1998-04-15 2001-07-01 Esteve Labor Dr Tienilazolilalcoxietanaminas, su preparacion y su aplicacion como medicamentos.
US20040010004A1 (en) * 2000-01-17 2004-01-15 Naoki Tsuchiya Benzimidazole derivatives
CN1187337C (zh) 1998-07-15 2005-02-02 帝人株式会社 硫代苯并咪唑衍生物
NZ520028A (en) * 2000-01-17 2004-07-30 Teijin Ltd Benzimidazole derivatives
EP1792614A1 (fr) * 2001-02-22 2007-06-06 Teijin Pharma Limited Dérivés de benzo[b]thiophène
KR20030031486A (ko) * 2001-05-07 2003-04-21 데이진 가부시키가이샤 3-히드록시메틸벤조[ｂ]티오펜 유도체 및 그의 제조 방법
US20040122042A1 (en) * 2001-08-24 2004-06-24 Hidenori Urata Drugs containing chymase inhibitor and ace inhibitors as the active ingredients
CL2004001034A1 (es) 2003-05-14 2005-03-28 Teijin Pharma Ltd Formas cristalinas de acido 4-(1-((,etilbenzotiofen-3-il)me til)benzimidazol-2-iltio)butanoico; procedimiento de preparacion de las formas cristalinas; composicion farmaceutica; y su uso para el tratamiento de enfermedades inflamatorias, alergicas, r

Also Published As

Publication number Publication date
CA2523978A1 (fr) 2004-11-25
UA81493C2 (en) 2008-01-10
CO5660259A2 (es) 2006-07-31
EP1626048A4 (fr) 2008-11-12
RU2005138868A (ru) 2006-07-10
CN1788007A (zh) 2006-06-14
ECSP056162A (es) 2006-04-19
AR044340A1 (es) 2005-09-07
TNSN05288A1 (en) 2007-07-10
NO20055181L (no) 2006-01-24
RU2332417C2 (ru) 2008-08-27
EP1626048A1 (fr) 2006-02-15
NO20055181D0 (no) 2005-11-03
US20060293375A1 (en) 2006-12-28
SA04250117B1 (ar) 2009-09-02
JPWO2004101551A1 (ja) 2006-07-13
BRPI0410266A (pt) 2006-05-16
NZ542978A (en) 2009-04-30
US7649008B2 (en) 2010-01-19
AU2004238708A1 (en) 2004-11-25
ZA200508640B (en) 2007-02-28
MXPA05011851A (es) 2006-02-17
IS8177A (is) 2005-12-13
KR20060011997A (ko) 2006-02-06
PE20050203A1 (es) 2005-03-26
CL2004001034A1 (es) 2005-03-28
WO2004101551A1 (fr) 2004-11-25
TW200505911A (en) 2005-02-16

Similar Documents

Publication Publication Date Title
PT1496865E (pt) Processo para a preparacao de cristais, cristais assim obtidos e sua utilizacao em formulacoes farmaceuticas
EA200601584A1 (ru) Замещённые глюкопиранозилом бензольные производные, содержащие эти соединения лекарственные средства, их применение и способ их получения
NO20060774L (no) Kinolin- og kinazolinderivater som har affinitet for 5HT1-typereseptorer
DE50307267D1 (de) Dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel
MXPA04004464A (es) Compuestos de heteroarilo sustituido con azabiciclo para el tratamiento de enfermedades.
NO20085078L (no) Nye forbindelser
CA2462453A1 (fr) Composes d'heteoraryle fusionne substitues par azabicyclo utiles pour le traitement de maladies
SE0102300D0 (sv) Compounds
FR2820342B1 (fr) Procede de preparation de membranes zeolithiques supportees par cristallisation controlee en temperature
MA27069A1 (fr) FORMES POLYMORPHES DE RIFAXIMIN, PROCEDES POUR LEUR PRODUCTION ET USAGE DE MeME DANS LES PREPARATIONS MEDICINALES
NO20062370L (no) Amidderivater
NO20064151L (no) Nye forbindelser
PE20050078A1 (es) Derivados de pirrolidona como inhibidores de maob
JP2012149084A (ja) イオンチャネルのモジュレーターとして有用なキノリン誘導体
EP1755596A4 (fr) Procede pour la preparation de bisulfate d'atazanavir et de nouvelles formes
NO20044041L (no) Okso-azabisykliske forbindelser
UY24504A1 (es) Dihidrato de eprosartano y un procedimiento para su produccion y formulacion
MA27133A1 (fr) Nouvelles formes polymorphes cristallines d'hydrochlorure de lercanidipine et procede de fabrication associe
DE69207301T2 (de) Substituierte 3-Piperazinylalkyl 2,3-Dihydro-4H-1,3-Benzoxazin-4-One, deren Herstellung und Verwendung in Heilkunde
NO20064951L (no) 1,3,4-oksadiazol-2-oner som PPAR delta-modulatorer og deres anvendelse
DE50311923D1 (de) Harnstoff- und urethan-substituierte acylharnstoffe, verfahren zu deren herstellung und deren verwendung als arzneimittel
TW200804348A (en) Quinazolines useful as modulators of voltage gated ion channels
ATE487478T1 (de) Herstellung eines neuen pharmazeutisch geeigneten losartan-salzes und von seinen formen mittels neuer reinigungs- und isolationsverfahren
TNSN05288A1 (en) Crystal of benzimidazole derivative and process for producing the same
MEP37108A (en) Stable polymorph of bifeprunox mesilate (7-[4-([1,1'-biphenyl]-3-yl-metheyl)-1-piperazinyl]-2(3h)-benzoxazolone monomethansulfonate